BD Korea’s Strategy on Medical Aesthetics at COPHEX 2025

BD Korea recently showcased its approach to medical aesthetics at the COPHEX 2025 exhibition held in Ilsan Kintex. As BD is a well-known global medical device manufacturer, the introduction of their new technologies and strategies drew significant attention. This blog post will delve into their participation and the highlights of the event.

Overview of BD Korea’s Participation

BD Korea utilized COPHEX 2025 to unveil the latest trends in managing obesity and medical aesthetics. They presented their innovative technologies across various segments:

Biopharmaceuticals: Focused on solutions for drug delivery tailored to developmental phases.
Vaccines: Highlighted their cutting-edge methods for accurate and efficient vaccine delivery.
Acute Diseases & Hyaluronic Acid: BD has prioritized fast and effective responses to acute medical needs.
Technical Support Services: Offered comprehensive support for BD products, aiding in development and commercialization.

Key Sessions at the Event

BD Korea organized two significant seminars focusing on market trends and their technological strategies.

GLP-1 Obesity Treatment Insights

Market Trends and Strategy: First seminar led by BD Korea and IQVIA shared insights on GLP-1 drugs. The trend points to treating obesity as a disease rather than a lifestyle choice.
By focusing on chronic diseases like cardiovascular risks and Type 2 diabetes, BD is addressing a crucial shift in obesity treatment.

Innovative Device Introduction

BD Vystra Pen Device: A self-injection technology designed for user convenience and safety, Vystra caters to the needs of long-term care for patients using GLP-1 medications.
BD Hylok Syringe: This prefilled syringe, designed for high-viscosity hyaluronic acid fillers, prevents common issues like leakage or detachment during procedures.

These sessions provided insightful discussions on advancing obesity treatments and enhancing medical aesthetics.

Technological Highlights

BD’s technology was a focal point, aiming to cater to current market needs, particularly in the healthcare and aesthetics sectors.

GLP-1 Devices: Emphasized device simplicity, infection prevention, dosing flexibility, and reduced development time.
Hylok Prefilled Syringe: Integrated durable design for high-viscosity fillers, addressing practitioner concerns during administrations.

Future Directions in Medical Aesthetics

BD Korea continues to prioritize advancements that align with market needs:

Focus on the expansion of therapy use cases and sustained release formulations.
Support domestic pharmaceutical companies with product development and commercialization.

Final Thoughts

COPHEX 2025 served as a platform for BD Korea to reinforce its leadership in drug delivery systems and medical aesthetics. Their approach reflects a thorough understanding of the market’s evolving needs and provides a foundation for future innovations. As you explore medical aesthetics and drug delivery, BD’s strategies at COPHEX 2025 provide key insights into the sector’s current dynamics.